Information Provided By:
Fly News Breaks for April 4, 2017
SCMP
Apr 4, 2017 | 08:18 EDT
Leerink analyst Jason Gerberry notes that Sucampo acquired Vtesse for $200M and in the process bolstered its late-stage pipeline by adding pivotal-stage VTS-270 for treatment of Niemann Pick Disease Type C. The analyst says Sucampo appears to have paid a fair price for the asset, which could deliver meaningful upside if Phase 3 data are positive in 1H18. He reiterates a Market Perform rating and $10.65 price target on the shares.
News For SCMP From the Last 2 Days
There are no results for your query SCMP